(58 H		Application Number	10/081,526
TRANSMITT	AL	Filing Date	February 21, 2002
FORM		First Named Inventor	Wilkinson
(to be used for all correspondence afte	r initial filing)	Group Art Unit	Unassigned
		Examiner Name	Unassigned
Total Number of Pages in This Submis	ssion 6	Attorney Docket Numbe	or 0174.210US
	ENCLOS	SURES (check all that ap	ply)
Fee Transmittal Form		nent Papers Application)	After Allowance Communication to Group
Fee Attached	Drawing	ı(s)	Appeal Communication to Boar of Appeals and Interferences
Amendment / Response	Licensir	ng-related Papers	Appeal Communication to Grou
After Final	Petition and Acc	Routing Slip (PTO/SB/69) companying Petition	Proprietary Information
Affidavits/declaration(s)		to Convert to a enal Application	Status Letter
Extension of Time Request	Power	of Attorney, Revocation of Correspondence	Additional Enclosure(s) (please identify below):
Express Abandonment Request	Termina	al Disclaimer	Form 1449; Refs.: 1-57 Receipt of Acknowledgement Postcard
X Information Disclosure Statement		ntity Statement	rostcaru
Certified Copy of Priority Document(s)		o Charge Deposit Account	
Response to Missing Parts/ Incomplete Application	this paper or du		or any additional fees associated with ation, including any extensions of time
Response to Missing Parts under 37 CFR	Remarks		
1.52 or 1.53			
SIGNATU	RE OF APPLI	CANT, ATTORNEY, OR	AGENT
Firm or	Christo	pher M. Holman Reg. 1	No. 40,021
	0		
or Individual name Signature	Christo	pher M. Holman Reg. 1	No. 40,021
Date 7(

CERTIFICATE OF MAILING						
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an						
envelope addressed to: Ass	sistant Commissioner for Patents, Washington, D.C. 20231 on this date: 7 - 10 - 2002					
Typed or printed name	JULIE K. MAUSEN					
	1 0: -11 00					

Signature

Dale Dale

7-10-2002

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents, Washington, D.C. 20231

on July 10, 2002



Julie K. Mausen

Attorney Docket No. 0174.210US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Jack Wilkinson et al.

Application No.: 10/081,526

Filed: February 21, 2002

METHODS FOR IMPROVING

OR ALTERING

PROMOTER/ENHANCER

PROPERTIES

Examiner: Unassigned

Art Unit: Unassigned

INFORMATION DISCLOSURE

STATEMENT UNDER 37 CFR § 1.97 and

<u>§ 1.98</u>

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

For:

The references cited on attached form PTO-SB/08 are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicants believe that <u>no fee is required</u> for submission of this statement, since it is being submitted prior to a first Office action on the merits. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0990. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Christopher M. Holman

Reg. No. 40,021

Maxygen, Inc.
Patent Department
515 Galveston Drive
Redwood City, California 94063

Telephone: (650) 298-5300 Facsimile: (650) 298-5446

Customer No. 30560

Complete if Known Substitute for form 1449A-B/P Application Number 10/081,526 INFORMATION DISCLOSURE ADEMAN February 21, 2002 Filing Date STATEMENT BY APPLICAN First Named Inventor Jack Wilkinson Group Art Unit Unassigned **Examiner Name** Unassigned (use as many sheets as necessary) **Attorney Docket Number** 0174.210US

			U.	S. PATENT DOCUMENTS		
Examiner	Cite	U.S. Patent Do Number	Kind Code	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, lines, Where Relevant Passages
Initials	No.		(if known)		MM-DD-YYYY	or Relevant Figures Appeal
	1	5,521,077		Khosla et al.	05/28/96	
	2	5,723,323		Kauffman et al.	03/03/98	
	3	5,824,469		Horwitz et al.	10/20/98	
	4	5,965,408		Short	10/12/99	
	5	6,171,820	B1	Short	01/09/01	
	6	6,238,884	B1	Short et al.	05/29/01	
	7	6,319,714	B1	Crameri et al.	11/20/01	
	8	6,358,740	B1	Patten et al.	03/19/02	
	9	6,368,861	B1	Crameri et al	04/09/02	

				FOREIGI	N PATENT DOCUMEN	TS		
Examiner Initials	Cite No.	Office	Foreign Patent Docu Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	т
	10	wo	97/07205	A1	Novo Nordisk	02/27/1997		
	11	wo	97/20078	A1	Affymax Technologies N.V.	06/05/1997		
	12	wo	97/25410	A1	Novo Nordisk	07/17/1997		
	13	wo	97/35957	A1	Maxygen, Inc.	10/02/1997		
	14	wo	97/35966	A1	Maxygen, Inc.	10/02/1997		
	15	wo	98/27230	A1	Maxygen, Inc.	06/25/1998		
	16	wo	98/28416	A1	Novo Nordisk	07/02/1998		
	17	wo	98/41622	A1	Novo Nordisk	09/24/1998		
	18	wo	98/41623	A1	Novo Nordisk	09/24/1998		
	19	wo	98/41653	A1	Novo Nordisk	09/24/1998		
	20	wo	98/42832	A1	California Institute of Technology	10/01/1998		
	21	wo	99/23236	A1	Diversa Corporation	05/14/1999		
	22	wo	99/29902	A1	California Institute of Technology	06/17/1999		

Date	
- Daile	
l Considered I	
	Date Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT B

RADEMAN
APPLICANT

ω ₁ C(omplete it Known	
Application Number	10/081,526	
Iling Date	February 21, 2002	
First Named Inventor	Jack Wilkinson et al.	
Group Art Unit	Unassigned	
Examiner Name	Unassigned	
Attorney Docket Number	0174.210US	


(use as many sheets as necessary)

	23	wo	99/65927	A1	Maxygen, Inc.	12/23/1999	
	24	wo	00/04190	A1	Maxygen, Inc.	01/27/2000	
	25	wo	00/42561	A1	Maxygen, Inc.	07/20/2000	
	26	wo	00/52155	A1	Maxygen, Inc.	09/08/2000	
-	27	wo	00/53744	A1	Diversa Corporation	09/14/2000	
	28	wo	00/58517	A1	Diversa Corporation	10/03/2000	

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	_
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	29	CHANG, C., et al. "Evolution of a cytokine using DNA family shuffling," <i>Nature Biotechnology</i> , (1999) 17:793-797.	
	30	CHRISTIANS, F.C. et al., "Directed evolution of thymidine kinase for AZT phosphorylation using DNA family shuffling," <i>Nature Biotechnology</i> , (1999) 17:259-264.	
	31	CHUZHANOVA, NADIA A.et al., "Promoter shuffling has occurred during the evolution of the vertebrate growth hormone gene", <i>Gene</i> , (2000) 254:9-18	
	32	COCO, WAYNE M. et al "DNA shuffling method for generating highly recombined genes and evolved enzymes" <i>Nature Biotechnology</i> , (2001) 19:354-359	
	33	CRAMERI, A. et al., "Combinatorial Multiple Cassette Mutagenesis Creates All the Permutations of Mutant and Wild-Type Sequences", <i>BioTechniques</i> , (1985) 18:194-196	
	34	CRAMERI, A. et al. "Construction and evolution of antibody-phage libraries by DNA shuffling", <i>Nature Medicine</i> , (1996) 2:100-103.	
	35	CRAMERI, A. et al. "Improved green fluorescent protein by molecular evolution using DNA shuffling", <i>Nature Biotechnology</i> , (1996) 14:315-319	
	36	CRAMERI, A. et al., "Molecular evolution of an arsenate detoxification pathway by DNA shuffling", <i>Nature Biotechnology</i> , (1997) 15:436-438	
	37	CRAMERI, A. et al., "DNA shuffling of a family of genes from diverse species accelerates directed evolution", <i>Nature</i> , (1998) 391:288-291.	
-	38	LASSNER, MICHAEL et al., "Directed molecular evolution in plant improvement", Current Opinion in Plant Biology, (2001) 4:152-156	
	39	LI, XUYANG et al., "Synthetic muscle promoters: activities exceeding naturally occurring regulatory sequences", <i>Nature Biotechnology</i> , (1999) 17:241-245	
,	40	MERZ, ASTRID et al., "Improving the Catalytic Activity of a Thermophilic Enzyme at Low Temperatures", <i>Biochemistry</i> , (2000) 39:880-889	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



0174.210US

Attorney Docket Number

41	MINSHULL, JEREMY et al., "Protein evolution by molecular breeding", Current Opinion in Chemical Biology, (1999) 3:284-290	
42	NESS, JON E. et al., "DNA shuffling of subgenominc sequences of subtilisin", <i>Nature Biotechnology</i> , (1999) 17:893-896.	
43	NESS, JON E. et al., "Molecular Breeding: The Natural Approach To Protein Design", Advances In Protein Chemistry, (2001) 55:261-292	
44	NI, MIN et al., "Strength and tissue specificity of chimeric promoters derived from the octopine and mannopine synthase genes", <i>The Plant Journal</i> , (1995) 7:661-676	
45	PATTEN, PHILIP A. et al., "Applications of DNA shuffling to pharmaceuticals and vaccines", Current Opinion in Biotechnology, (1997) 8:724-739	
46	POWELL, SHARON K. et al., "Breeding of retroviruses by DNA shuffling for improved stability and processing yields", <i>Nature Biotechnology</i> , (2000) 18:1279-1282	
47	PUNNONEN, JUHA et al., "Molecular Breeding by DNA Shuffling", Science and Medicine, (2000) 38-47	
48	PUNNONEN, JUHA., "Molecular Breeding of Allergy Vaccines and Antiallergic Cytokines", Int.Arch. Allergy Immunol., (2000)121:173-182	
49	SOONG, NAY-WEI, et al., "Molecular breeding of viruses", <i>Nature Genetics</i> , (2000) 25:436-439	
50	STEMMER, WILLEM P.C. "Rapid evolution of a protein in vitro by DNA shuffling", <i>Nature</i> , (1994) 370:389-391	
51	STEMMER, WILLEM P.C "DNA shuffling by random fragmentation and reassembly: In vitro recombination for molecular evolution", <i>Proc. Natl. Acad. Sci. USA</i> , (1994) 91:10747-10751	
52	STEMMER, WILLEM P.C "Searching Sequence Space", Bio/technology, (1995) 13:549-553	
53	STEMMER, WILLEM P.C "Sexual PCR and Assembly PCR", Encyclopedia of Molecular Biology and Molecular Medicine, (1996) 5:447-457	
54	STEMMER, WILLEM P.C et al., "Molecular breeding of viruses for targeting and other clinical properties" <i>Tumor Targeting</i> , (1999) 4:1-4	
55	TOBIN, MATTEW B. et al., "Directed evolution: the 'rational' basis for 'irrational' design", Current Opinion in Structural Biology, (2000) 10:421-427	
56	WHALEN, ROBERT G. et al., "DNA shuffling and vaccines", Current Opinion in Molecular	

APPLICANT

Examiner	Date
Cimpolina	
Signature (Considered

ZHANG, JI-HU et al., "Directed evolution of a fucosidase from a galactosidase by DNA

shuffling and screening", Proc. Natl. Acad. Sci. USA, (1997) 94:4504-4509

Therapeutics, (2001) 3:31-36

57

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.